Valiant Laboratories has scheduled its IPO, with the offering set to commence on September 27 and conclude on October 3. The company aims to raise approximately ₹152 crores through the IPO, which will consist of a fresh issue of 11,556,000 equity shares, each with a face value of ₹10. The allocation percentages for various investor categories are as follows: 35% for retail investors, 50% for qualified institutional buyers (QIBs), and 15% for high-net-worth individuals (HNIs).
About Valiant Laboratories
Founded in 2021, Valiant Laboratories is a company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and Bulk Drugs, with a primary focus on producing Paracetamol. These bulk drugs and APIs serve as essential raw materials for the production of finished dosage forms or formulations.
Valiant Laboratories operates its manufacturing facility in Palghar, located in the state of Maharashtra, India. The facility spans across an area of approximately 2,000 square meters and boasts a combined annual installed capacity of 9,000 metric tons.
In terms of its revenue breakdown, for the financial years ending on March 31, 2023, 2022, and 2021, sales generated outside of India accounted for 0.39%, 0.60%, and 0.33% of the total revenue from operations, respectively. Over the period from FY 2017 to FY 2023, the revenue from operations displayed robust growth, achieving a Compound Annual Growth Rate (CAGR) of 23.90%. Furthermore, the restated profit after tax also demonstrated impressive growth, with a CAGR of 26.81% during the same period from FY 2017 to FY 2023.
The objects of the issue for Valiant Laboratories are as follows:
Investment in Wholly-Owned Subsidiary (VASPL): Part of the funds raised through the IPO will be allocated towards investing in Valiant Advanced Sciences Private Limited (VASPL), a wholly-owned subsidiary. This investment will be used to finance the capital expenditure requirements associated with the establishment of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat, which is referred to as the “Proposed Facility.”
Investment in VASPL for Working Capital: The IPO proceeds will also be utilized to provide funding for the working capital needs of Valiant Advanced Sciences Private Limited (VASPL). This allocation of funds will support the subsidiary’s ongoing operational and liquidity requirements.
General Corporate Purposes: In addition to the specific investments in the subsidiary and its working capital, a portion of the funds raised through the IPO will be earmarked for general corporate purposes. These purposes may include meeting operational expenses, repayment of existing debts, or other routine corporate needs.
Peer Group Companies
Promoters
Granules India Ltd
Shantilal Shivji Vora
Jagsonpal Pharmaceuticals Limited
Dhanvallabh Ventures LLP
IPO Registrar
IPO Allotment Status Check
Link Intime India Private Limited
Check Valiant Laboratories IPO allotment status on Linkintime website allotment URL. Click Here
Naren is a finance graduate who is passionate about cryptocurrency and blockchain technology. He demonstrates his expertise in these subjects by writing for cryptoetf.in. Thanks to his finance background, he is able to write effectively about cryptocurrency.
